Device Trial Radar · NCT04434209
A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
19
Actual
Start
Jan 19, 2021
Primary completion
Feb 14, 2022
Study completion Feb 14, 2022
Sponsor
- Lead sponsor
- BioMérieuxNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 16, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Biomarkers that provide an early indicator of kidney stress could be useful in clinical practice to detect silent episodes of acute kidney injury (AKI) or for early identification of subjects at risk of AKI. Two urinary biomarkers have been identified as early indicators of AKI. The NephroCheck® test is a commercially available test that uses these biomarkers, and this study assesses the use of these in reducing negative clinical outcomes for patients with sepsis-associated AKI. The study will enroll subjects diagnosed with sepsis, including septic shock, who will be randomly assigned to either receive NephroCheck®-guided kidney-sparing and fast-tracking interventions; or to receive current Standard of Care assessment and treatment. NOTE: Participants are no longer being recruited to this study.
Conditions
- Sepsis
- Acute Kidney Injury
- Septic Shock
Interventions
Subject management guided by NephroCheck® testDevice
NephroCheck® is a device using biomarkers to identify subjects at risk of sepsis-associated acute kidney injury
Standard of CareOther
Standard of Care patient management
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of deaths, dialysis or progression of AKITime frame: Enrollment to 72 hours
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
LSU Health Sciences Center, 1541 Kings Highway
Shreveport, Louisiana
Brigham and Womens Hospital, 75 Francis Street
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center, 1275 York Avenue
New York, New York
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.